Photo credit: www.sciencedaily.com
Innovative Therapy for C. difficile Infection Developed by Penn State Researchers
A new therapy utilizing a synthetic microbiome has shown promise in protecting against serious symptoms associated with infections caused by the bacterium Clostridioides difficile (C. difficile), known for its difficulty to treat and potential dangers in humans. This research, conducted by a team from Penn State University, explores a novel approach aimed at mitigating the significant health risks posed by this pathogen, which can lead to severe diarrhea, abdominal discomfort, and inflammatory bowel issues.
C. difficile overgrowth often occurs when the delicate balance of the gut microbiome—the community of trillions of microorganisms crucial for maintaining health—becomes disrupted. The findings from this study suggest that a new probiotic strategy could emerge, offering an alternative treatment for C. difficile infections without relying on antibiotics or standard fecal microbiota transplants.
This innovative treatment avoids the use of actual fecal matter, which is a core component of traditional fecal transplants. Instead, the therapy focuses on a smaller selection of highly specific bacterial strains that have proven effective in suppressing C. difficile. In animal trials, the synthetic microbiome therapy matched the effectiveness of human fecal transplants but came with fewer safety risks.
The study’s results were published in the journal Cell Host & Microbe. Following these findings, the research team has also taken steps to patent their innovative approach.
Senior author Jordan Bisanz, an assistant professor specializing in biochemistry and molecular biology, highlighted the need for a more targeted strategy in microbiome therapies. “The key is to enhance our microbiome interventions by building on fundamental scientific discoveries,” he noted.
By investigating how complex microbial communities influence host health, the team aims to develop more specific therapies targeting C. difficile infections.
Generally, the balance within the microbiome allows for mutual regulation among various organisms. While many individuals may carry C. difficile in their guts without any symptoms, antibiotic treatments can inadvertently create conditions favorable for the bacterium’s overgrowth by eliminating beneficial bacteria. In fact, C. difficile is responsible for 15% to 25% of cases of antibiotic-associated diarrhea, particularly following hospital visits.
Treating C. difficile infections presents significant challenges. Traditional antibiotics are often ineffective due to the bacterium’s resistance to drug treatments. They can also further disrupt the gut microbiome, which can lead to recurring infections. According to the Centers for Disease Control and Prevention, there are approximately 500,000 C. difficile infections annually in the United States, which incur around $1.5 billion in healthcare costs.
One established method that has demonstrated success involves fecal microbiota transplants, which aim to restore a healthy microbiome balance. However, this approach carries inherent risks.
Bisanz described fecal transplants as a somewhat random assortment of bacteria, much like a pharmacist mixing various medications. “We can’t be certain what’s included in that mixture,” he explained, pointing out the potential for including harmful bacteria.
Motivated by these concerns, the researchers sought to identify the precise microorganisms that could effectively inhibit C. difficile colonization. They explored data on the human microbiome from a dozen previous studies, utilizing machine learning techniques to determine which bacteria were beneficial or detrimental in relation to C. difficile.
They identified 37 bacterial strains that negatively correlate with C. difficile, meaning their presence often prevents infection. Conversely, 25 strains were found to be positively correlated with C. difficile infection. Using this data, the researchers synthesized a tailored version of a fecal transplant by combining bacteria known to suppress C. difficile.
In laboratory settings and trials involving mice, the synthetic microbiome therapy significantly thwarted the growth of C. difficile and demonstrated efficacy comparable to that of traditional fecal transplants. Furthermore, it was effective in preventing severe illness and reducing the likelihood of relapse or recurrent infections linked to antibiotic use.
Through experimentation, the researchers pinpointed a single bacterial strain, Peptostreptococcus, as particularly crucial in curtailing C. difficile. This strain alone proved equally effective as a fecal transplant in preventing infection in mouse models.
“With the presence of this specific strain, C. difficile does not thrive,” Bisanz clarified, underscoring its potency as a suppressor. He noted that this strain excels in competing for the amino acid proline, which C. difficile needs for growth. While previous studies suggested that bile acid metabolism was vital for resisting C. difficile, the new findings place greater importance on the competitive dynamics involving proline.
Bisanz remarked that the insights gained from this research could also apply to understanding host-microbe interactions in conditions such as inflammatory bowel disease, paving the way for the development of new therapies.
“Our objective is to cultivate these microbes for use as targeted therapeutic agents,” he stated, highlighting the potential for advanced microbiome science to influence future medical treatments.
Other contributors to the research included Shuchang Tian and Min Soo Kim, both doctoral students in biochemistry and molecular biology; postdoctoral researchers Jingcheng Zhao and Fuhua Hao; undergraduate student Kerim Heber; and faculty members David Koslicki and Andrew Patterson.
This research was supported by funding from several National Institutes of Health entities and the Huck Life Sciences Institute at Penn State University.
Source
www.sciencedaily.com